Exact Mass: 559.1400118

Exact Mass Matches: 559.1400118

Found 62 metabolites which its exact mass value is equals to given mass value 559.1400118, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

dTDP-D-desosamine

dTDP-D-desosamine; dTDP-3-dimethylamino-3,4,6-trideoxy-D-glucose; dTDP-alpha-D-desosamine; dTDP-3-dimethylamino-3,4,6-trideoxy-alpha-D-glucose; dTDP-3-dimethylamino-3,4,6-trideoxy-alpha-D-glucopyranose

C18H31N3O13P2 (559.1332056)


   
   

dTDP-beta-L-evernosamine

dTDP-beta-L-evernosamine; dTDP-3-amino-2,3,6-trideoxy-3-C-methyl-4-O-methyl-beta-L-arabino-hexopyranose

C18H31N3O13P2 (559.1332056)


   

dTDP-4-ethylamino-3-O-methyl-2,4-dideoxy-L-threo-pentopyranose

dTDP-4-ethylamino-3-O-methyl-2,4-dideoxy-L-threo-pentopyranose

C18H31N3O13P2 (559.1332056)


   
   
   

Neoacrimarine K

1-hydroxy-4-[8-(2-hydroxypropan-2-yl)-2-oxo-2H,8H,9H-furo[2,3-h]chromen-9-yl]-3,5,6-trimethoxy-10-methyl-9,10-dihydroacridin-9-one

C31H29NO9 (559.1842224000001)


Neoacrimarine K is found in citrus. Neoacrimarine K is an alkaloid from the roots of Citrus paradisi (grapefruit). Alkaloid from the roots of Citrus paradisi (grapefruit). Neoacrimarine K is found in citrus.

   

Gadoteridol

3-methyl-16,19,24-trioxo-2,17,18,25-tetraoxa-5lambda5,8lambda5,11lambda5,14lambda5-tetraaza-1-gadolinaoctacyclo[9.6.3.3^{1,8}.2^{5,14}.0^{1,5}.0^{1,8}.0^{1,11}.0^{1,14}]pentacosan-2-ium-5,8,11,14-tetrakis(ylium)-1,1-diuide

C17H29GdN4O7 (559.1277253999999)


Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts. V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media

   

Infigratinib

N-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-N-methylcarbamimidic acid

C26H31Cl2N7O3 (559.1865316)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EN - Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D000970 - Antineoplastic Agents

   

Acetic acid, 2-(4-((5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazol-1-yl)sulfonyl)phenoxy)-

Acetic acid, 2-(4-((5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazol-1-yl)sulfonyl)phenoxy)-

C25H25N3O8S2 (559.108301)


   

8-(5-Chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide

5-Chloro-N-[1-(4-fluorophenyl)-3-(C-hydroxycarbonimidoyl)-1H,4H,5H-benzo[g]indazol-8-yl]-2-(4-methylpiperazin-1-yl)pyridine-4-carboximidate

C29H27ClFN7O2 (559.1898684)


   
   
   

convolutamide A|N-Tetradecanoyl-Deacylconvolutamide

convolutamide A|N-Tetradecanoyl-Deacylconvolutamide

C24H35Br2NO4 (559.0932670000001)


   
   

Cys Asp His Trp

(3S)-3-[(2R)-2-amino-3-sulfanylpropanamido]-3-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Cys Asp Trp His

(3S)-3-[(2R)-2-amino-3-sulfanylpropanamido]-3-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Cys His Asp Trp

(3S)-3-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Cys His Trp Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(1H-indol-3-yl)propanamido]butanedioic acid

C24H29N7O7S (559.1849084)


   

Cys Trp Asp His

(3S)-3-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Cys Trp His Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-imidazol-4-yl)propanamido]butanedioic acid

C24H29N7O7S (559.1849084)


   

Asp Cys His Trp

(3S)-3-amino-3-{[(1R)-1-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-sulfanylethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Asp Cys Trp His

(3S)-3-amino-3-{[(1R)-1-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-sulfanylethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Asp His Cys Trp

(3S)-3-amino-3-{[(1S)-1-{[(1R)-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-sulfanylethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Asp His Trp Cys

(3S)-3-amino-3-{[(1S)-1-{[(1S)-1-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Asp Trp Cys His

(3S)-3-amino-3-{[(1S)-1-{[(1R)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-sulfanylethyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Asp Trp His Cys

(3S)-3-amino-3-{[(1S)-1-{[(1S)-1-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

His Cys Asp Trp

(3S)-3-[(2R)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanamido]-3-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

His Cys Trp Asp

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]butanedioic acid

C24H29N7O7S (559.1849084)


   

His Asp Cys Trp

(3S)-3-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-{[(1R)-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}-2-sulfanylethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

His Asp Trp Cys

(3S)-3-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-{[(1S)-1-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

His Trp Cys Asp

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]butanedioic acid

C24H29N7O7S (559.1849084)


   

His Trp Asp Cys

(3S)-3-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Trp Cys Asp His

(3S)-3-[(2R)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Trp Cys His Asp

(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-(1H-imidazol-4-yl)propanamido]butanedioic acid

C24H29N7O7S (559.1849084)


   

Trp Asp Cys His

(3S)-3-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-{[(1R)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-sulfanylethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Trp Asp His Cys

(3S)-3-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-{[(1S)-1-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Trp His Cys Asp

(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-sulfanylpropanamido]butanedioic acid

C24H29N7O7S (559.1849084)


   

Trp His Asp Cys

(3S)-3-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}propanoic acid

C24H29N7O7S (559.1849084)


   

Gadoteridol

gadolinium(3+) ion 2-[4,7-bis(carboxylatomethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate

C17H29GdN4O7 (559.1277253999999)


V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media

   

Neoacrimarine K

1-hydroxy-4-[8-(2-hydroxypropan-2-yl)-2-oxo-2H,8H,9H-furo[2,3-h]chromen-9-yl]-3,5,6-trimethoxy-10-methyl-9,10-dihydroacridin-9-one

C31H29NO9 (559.1842224000001)


   

4-(4-METHYLTHIOPHEN-2-YL)-N-(4-(MORPHOLINOMETHYL)PHENYL)-7-TOSYL-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE

4-(4-METHYLTHIOPHEN-2-YL)-N-(4-(MORPHOLINOMETHYL)PHENYL)-7-TOSYL-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE

C29H29N5O3S2 (559.1711724)


   

Bis[1-(2-pyridylazo)-2-naphtholato]copper(II)

Bis[1-(2-pyridylazo)-2-naphtholato]copper(II)

C30H20CuN6O2 (559.094365)


   

aluminum phthalocyanine hydroxide

aluminum phthalocyanine hydroxide

C32H20AlN8O (559.15754)


   

GADOTERIC ACID

[2,2,2,2-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl-kappa(4)N(1),N(4),N(7),N(10))tetraacetato(3-)]gadolinium

C16H25GdN4O8 (559.091342)


V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media D064449 - Sequestering Agents > D002614 - Chelating Agents

   

2-(dimethylamino)-2-biphenylyl-palladium(ii) chloride dinorbornylphosphine complex

2-(dimethylamino)-2-biphenylyl-palladium(ii) chloride dinorbornylphosphine complex

C28H37ClNPPd (559.1386752000001)


   

7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine (-)-mandelate

7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine (-)-mandelate

C24H23F6N5O4 (559.165415)


   

4-Methylumbelliferyl 3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-b-D-glucopyranoside

4-Methylumbelliferyl 3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-b-D-glucopyranoside

C24H24F3NO11 (559.130139)


   

Galicaftor

Galicaftor

C28H21F4NO7 (559.1254084)


C87006 - Pharmacological Chaperone

   
   

8-(5-Chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide

8-(5-Chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide

C29H27ClFN7O2 (559.1898684)


   
   

Infigratinib

BGJ398 (NVP-BGJ398)

C26H31Cl2N7O3 (559.1865316)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EN - Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D000970 - Antineoplastic Agents

   

[6-(Diethylamino)-9-(2,4-disulfophenyl)xanthen-3-ylidene]-diethylazanium

[6-(Diethylamino)-9-(2,4-disulfophenyl)xanthen-3-ylidene]-diethylazanium

C27H31N2O7S2+ (559.1572596)


   

Gadolinium-HP-Do 3A

Gadolinium-HP-Do 3A

C17H29GdN4O7 (559.1277253999999)


V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media

   

2-[(2R,4aS,12aS)-5-methyl-6-oxo-8-(2,2,2-trifluoroethylsulfonylamino)-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(3-fluorophenyl)acetamide

2-[(2R,4aS,12aS)-5-methyl-6-oxo-8-(2,2,2-trifluoroethylsulfonylamino)-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(3-fluorophenyl)acetamide

C24H25F4N3O6S (559.1400118)


   
   

2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(6,7-dimethoxy-2H-1,3-benzodioxol-5-yl)-2-hydroxy-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid

2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(6,7-dimethoxy-2H-1,3-benzodioxol-5-yl)-2-hydroxy-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid

C22H29N3O12S (559.1471874000001)


   

(3s)-3-(3,4-dibromo-5-hydroxyphenyl)-3-hydroxy-1-tetradecanoylpyrrolidin-2-one

(3s)-3-(3,4-dibromo-5-hydroxyphenyl)-3-hydroxy-1-tetradecanoylpyrrolidin-2-one

C24H35Br2NO4 (559.0932670000001)